网站地图 加入收藏 中文 English
 
首页 中心概况 组织机构 研究队伍 科学研究 人才培养 交流合作 支撑服务 人才招聘 下载专区 联系我们
当前位置:首页 - 交流合作 - 生命科学论坛
生命科学论坛
清华大学生物论坛 讲座
发布时间:2012-12-05关键字:清华大学生物论坛

Peter Tontonoz, M.D., Ph.D.

Professor, Department of Pathology and Laboratory Medicine, UCLA
Investigator, Howard Hughes Medical Institute
 
Education:                      
M.D., Harvard Medical School, Boston, MA (1996)
Ph.D., Harvard University, Cambridge, MA (1996) Department of Genetics
B.A., Wesleyan University, Middletown, CT (1989)High Honors in Molecular Biology and Biochemistry
 
Experience:                     
Professor (2006-present)Department of Pathology and Laboratory Medicine, UCLA
Investigator (2000-present)Howard Hughes Medical Institute
Co-Director (2012-present)UCSD/UCLA Diabetes Research Center (DRC)
Associate Professor with Tenure (2002-2006)Department of Pathology and Laboratory Medicine, UCLA
Assistant Professor (1999-2002)Department of Pathology and Laboratory Medicine, UCLA
Postdoctoral Fellow (1996-99)The Salk Institute, Laboratory of Dr. Ronald Evans
 
Topic:Nuclear control of cholesterol metabolism
 
Abstract
The Liver X Receptors (LXRs) are nuclear receptors that play central roles in the transcriptional control of lipid metabolism. LXRs function as nuclear cholesterol sensors that are activated in response to elevated intracellular cholesterol levels in multiple cell types. Once activated, LXRs induce the expression of an array of genes involved in cholesterol absorption, efflux, transport and excretion. They also inhibitcholesterol uptake by inducing the ubiquitination and degradation of the LDL receptor. In addition to their function in lipid metabolism, LXRs modulate immune and inflammatory responses cell of both the innate and acquired immune systems. Synthetic LXR agonists promote cholesterol efflux and inhibit inflammation in vivo and inhibit the development of atherosclerosis in animal models. Loss of LXR expression in mice leads to pathologic lipid accumulation, atherosclerosis and the development of autoimmune disease. The ability of LXRs to integrate metabolic and inflammatory signaling makes them potentially attractive targets for intervention in human metabolic disease.
 
Venue: Room143, New Biology Building, THU
Time: Dec.11 (Tuesday), 2012; 16:30
Host: Prof. Peng Li

 




版权所有 成品直播app大全免费下载/高清免费/完整版 京ICP备15006448号-5